Dublin, April 20, 2016 -- Research and Markets has announced the addition of the "Virus Filtration Market - Global Forecast to 2020" report to their offering.
The global virus filtration market is projected to reach USD 3.25 billion by 2020 from USD 1.82 billion in 2015, at a CAGR of 12.3% between 2015 and 2020.
By product, the market includes kits and reagents, filtration systems, other products and services. Based on application segment includes biologicals, medical devices, water purification, and air purification. The biologicals segment is further classified into, vaccines and therapeutics, blood and blood products, cellular and gene therapy products, tissue and tissue products and stem cell products.
The end user segments included in this report are pharmaceutical & biotechnology companies, contract research organizations, academic research institutes and medical devices companies. The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the virus filtration market in 2015.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the virus filtration market in 2015. Asia is expected to register the fastest growth during the forecast period.
The growth of this market is mainly driven by the rise in R&D expenditure, growth of biopharmaceutical industry, and increasing government support for pharmaceutical and biotechnology industry are driving factors of the virus filtration market. In addition, increasing adoption of single-use technologies is the latest trend observed in the virus filtration market.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Virus Filtration Market, By Product
7 Virus Filtration Market, By Application
8 Virus Filtration Market, By End User
9 Virus Filtration Market, By Region
10 Competitive Landscape
11 Company Profiles
Companies Mentioned:
- Asahi Kasei Medical Co.
- Charles River Laboratories International Inc.
- General Electric Company
- Lonza Group Ltd.
- Merck & Co.
- Pall Corporation
- Sartorius AG
- Sigma-Aldrich Corporation
- Thermo Fisher Scientific Inc.
- WuXi PharmaTech (Cayman) Inc.
For more information visit http://www.researchandmarkets.com/research/xsjt4d/virus_filtration
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Bill Ackman Eyes New Fund to Bet Against Market Complacency
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



